Generic Flyrcado Availability
Last updated on Apr 10, 2025.
Flyrcado is a brand name of flurpiridaz F 18, approved by the FDA in the following formulation(s):
FLYRCADO (flurpiridaz f-18 - solution;intravenous)
-
Manufacturer: GE HLTHCARE
Approval date: September 27, 2024
Strength(s): 5-55mCi/ML [RLD]
Is there a generic version of Flyrcado available?
No. There is currently no therapeutically equivalent version of Flyrcado available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flyrcado. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Contrast agents for myocardial perfusion imaging
Patent 7,344,702
Issued: March 18, 2008
Inventor(s): Casebier; David S. et al.
Assignee(s): Bristol-Myers Squibb Pharma Company (Princeton, NJ)The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
Patent expiration dates:
- May 26, 2026✓
- May 26, 2026
-
Contrast agents for myocardial perfusion imaging
Patent 8,226,929
Issued: July 24, 2012
Inventor(s): Casebier; David S. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
Patent expiration dates:
- June 21, 2028✓
- June 21, 2028
-
Methods and apparatus for synthesizing imaging agents, and intermediates thereof
Patent 8,936,777
Issued: January 20, 2015
Inventor(s): Cesati; Richard R. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., .sup.18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
Patent expiration dates:
- June 30, 2031✓
- June 30, 2031
-
Contrast agents for myocardial perfusion imaging
Patent 9,161,997
Issued: October 20, 2015
Inventor(s): Casebier; David S. et al.The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
Patent expiration dates:
- February 4, 2026✓✓✓
- February 4, 2026
-
Methods and apparatus for synthesizing imaging agents, and intermediates thereof
Patent 9,603,951
Issued: March 28, 2017
Inventor(s): Lazewatsky; Joel et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., .sup.18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
Patent expiration dates:
- May 2, 2031✓
- May 2, 2031
-
Stabilization of radiopharmaceutical compositions using ascorbic acid
Patent 9,687,571
Issued: June 27, 2017
Inventor(s): Castner; James F. et al.
Assignee(s): Lantheus Medical Imaging, Inc. (North Billerica, MA)Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.
Patent expiration dates:
- November 1, 2032✓✓
- November 1, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 27, 2029 - NEW CHEMICAL ENTITY
More about Flyrcado (flurpiridaz F 18)
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.